key: cord-0739973-6gqkmguo
authors: Motos, Anna; López-Gavín, Alexandre; Riera, Jordi; Ceccato, Adrián; Fernández-Barat, Laia; Bermejo-Martin, Jesús F; Ferrer, Ricard; de Gonzalo-Calvo, David; Menéndez, Rosario; Pérez-Arnal, Raquel; García-Gasulla, Dario; Rodriguez, Alejandro; Peñuelas, Oscar; Ángel Lorente, José; Almansa, Raquel; Gabarrus, Albert; Marin-Corral, Judith; Ricart, Pilar; Roche-Campo, Ferran; Sancho Chinesta, Susana; Socias, Lorenzo; Barbé, Ferran; Torres, Antoni
title: Higher frequency of comorbidities in fully vaccinated patients admitted to icu due to severe covid-19: a prospective, multicenter, observational study
date: 2021-11-25
journal: Eur Respir J
DOI: 10.1183/13993003.02275-2021
sha: 6d79aea823bce16a9196d6b96fe2ee9526579a76
doc_id: 739973
cord_uid: 6gqkmguo

The COVID-19 vaccination campaign in Spain began on 27 December 2020 [1]. To date, more than 36 million people have been fully vaccinated, with most of the population—namely 25.3 million people (69.1%) receiving BNT 162b2 (Pfizer/BioNTech) [1]. With respect to other vaccines and figures, 4.8 million (13.2%) people have received AZD1222 (Oxford/Astrazenca); 4.5 million (12.3%) mRNA-1273 (Moderna); and 2.0 million (5.4%) JNJ-78436735 (Janssen) [1].

To the Editor,

The COVID-19 vaccination campaign in Spain began on 27 December 2020 [1] . To date, more than 36 million people have been fully vaccinated, with most of the population-namely 25.3 million people (69.1%) receiving BNT 162b2 (Pfizer/BioNTech) [1] . With respect to other vaccines and figures, 4.8 million (13.2%) people have received AZD1222 (Oxford/Astrazenca); 4.5 million (12.3%) mRNA-1273 (Moderna); and 2.0 million (5.4%) JNJ-78436735 (Janssen) [1] .

The vaccination uptake has radically changed how the SARS-CoV-2 infection has impacted health care systems [2, 3] . Since the initiation of the campaign, a total of 19,705 patients with severe COVID-19 have required admission to intensive care unit (ICU) in Spain; the vast majority with no vaccination or an incomplete regimen [1] . Although vaccination has been shown to be notably effective, a few fully vaccinated patients could develop severe COVID-19 requiring ICU admission. To our knowledge, there is no description of this cohort of patients.

Within the CIBERESUCICOVID consortium [4] , we reported a prospective, multicentre and observational study that characterised fully vaccinated patients admitted to seven Spanish ICUs for severe COVID-19 between 25 January and 14 September 2021. These patients developed COVID-19 symptoms at least two weeks after administration of either a single-dose COVID-19 vaccine (JNJ-78436735) or the second dose of a two-dose vaccine. Exclusion criteria for this study included unconfirmed SARS-CoV-2 infection; ICU admission due to other causes; or incomplete vaccination status. Data was collected as previously described [4] . For the purpose of comparison, we included 105 consecutive, non-vaccinated adult patients with laboratory-confirmed SARS-CoV-2 infection requiring admission to the same seven ICUs between 25 January and 13 May 2021. years whilst only five patients aged < 50 years. Seventy-two percent (n=58) of these patients were male. All of the patients but two had at least one comorbidity, whereas 69.1 % (n=56) had three or more. The most frequent comorbidity was hypertension, being present in 61 (75.3%) patients. To our knowledge, this study is the first descriptive report of fully vaccinated patients requiring ICU admission due to severe COVID-19.The main finding of this study is that patients with specific comorbidities and full vaccination regimen may be at risk of developing severe COVID-19, even though vaccines have proven to be greatly effective in the general population [2, 3, 5] . Importantly, only 7% of patients with severe COVID-19 were fully vaccinated. We observed a notably high incidence of comorbidities in this population, especially as they relate with vascular disease (i.e., hypertension, diabetes mellitus and chronic renal disease) and immunosuppression status. When we compared this incidence with that of a non-vaccinated group of patients requiring ICU admission during coinciding periods, we observed a three-fold increase in immunosuppression; chronic respiratory disease, renal disease, diabetes mellitus and hypertension rates almost doubled. Of note, the median time between the onset of symptoms and hospital admission was significantly shorter for fully vaccinated cases than unvaccinated patients with COVID-19.

Investigators Contou et al. [6] published a study describing a second-wave French cohort of non-vaccinated patients. This cohort had similar or slightly increased comorbidity rates compared to those of our non-vaccinated group, albeit lower than that of our fully vaccinated patients. Juthani et al. [7] and Brosh-Nissimov et al. [8] had performed small reports of fully vaccinated patients that required hospitalization, including mild to severe patients. Like our study, both investigations found a high rate of comorbidities amongst severe or critically ill patients [7, 8] . In a case-control study including 35 fully vaccinated patients admitted to the ICU, Tenforde et al. found that the significant association between hospitalization for COVID-19 and decreased likelihood of vaccination was weaker in immunocompromised patients than immunocompetent patients [9] .

The implications of our findings are manyfold. First, these findings encourage discussion on the possible need for further interventions-such as the use of COVID-19 vaccine boosters-in this population. Some recent studies have already debated the practicality of a third dose of the vaccine [10] [11] [12] . Our data suggest that patients with comorbidities may benefit from these strategies.

Second, the substantial number of immunocompromised patients also suggests a poorer immune response in this population. Previous data have already demonstrated that some of these patients had low antibody levels after full vaccination [13, 14] . In this context, more personalised management of immunosuppressed patients, e.g., measuring antibody levels after vaccination, could prove to be a reasonable option.

Lastly, an increase in comorbidities directly impacts ICU management and the clinical outcomes of a fully vaccinated population. Some studies have already discussed prognosis in patients with previous comorbidities who develop COVID-19 [15, 16] . Indeed, we still observed high ICU mortality rate in fully vaccinated patients, reaching similar levels to previous reports including those in fully vaccinated patients [6-8, 17, 18] . Worsening of underlying illnesses and/or lower vaccine effectiveness in those patients may provide an explanation for these high rates [8] . Nevertheless, we observed no differences in mortality between both groups, despite higher rates of comorbidities in fully vaccinated patients. Of note, a final decision to not increase supportive measures was made in 16 (19.8%) patients.

Our study has some limitations, however. First, we collected data from a small cohort. A larger sample size would be ideal to confer a more robust generalisation of our results. Second, our control group was a small sample of the large, non-vaccinated population. As both study periods partially overlapped, it is also worth considering the role of emerging SARS-CoV-2 variants in these scenarios. Finally, we were not able to know the SARS-CoV-2 viral load and variant, or antibody titres before COVID-19 onset.

To conclude, only 7% of patients with severe COVID-19 were fully vaccinated. Nonetheless, a clinical scenario of severe COVID-19 disease requiring ICU admission is possible amongst the vaccinated population, especially in those with comorbidities and/or immunosuppression. Therefore, further interventions to improve vaccine response, including an additional dose, might be necessary for this population. Bacteriologic confirmation was not required. d Three patients had polymicrobial pneumonia in the fully vaccinated group, whilst two patients in the non-vaccinated group. e Acute renal injury was defined as an increase in serum creatinine by ≥0.3 mg/dL within 48 hours or as an increase in serum creatinine ≥1.5 times more than baseline. f Liver dysfunction was defined as an increase in blood bilirubin, alanine transaminase or aspartate transaminase twice the upper limit of the normal range.

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Other Viruses in the Acutely Ill N. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19

Hospitalizations in the United States

CIBERESUCICOVID: A strategic project for a better understanding and clinical management of COVID-19 in critical patients

Comparison between first and second wave among critically ill COVID-19 patients admitted to a French ICU: no prognostic improvement during the second wave?

Hospitalisation among vaccine breakthrough COVID-19 infections

BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

Antibody Response After a Third Dose of the mRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Covid-19: Third vaccine dose boosts immune response but may not be needed, say researchers

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Immunogenicity of BNT162b2 mRNA COVID-19 vaccine and SARS-CoV-2 infection in lung transplant recipients

Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis

Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study